

RESEARCH ARTICLE

Open Access

TNF- α Mediates Eosinophil Cationic Protein-induced Apoptosis in BEAS-2B Cells

Kun-Che Chang^{1†}, Chih-Wei Lo^{1†}, Tan-chi Fan², Margaret Dah-Tsyng Chang², Chih-Wen Shu¹, Chuan-Hsin Chang¹, Cheng-Ta Chung¹, Shun-lung Fang², Chih-Chung Chao¹, Jaw-Ji Tsai³, Yiu-Kay Lai^{1,4*}

Abstract

Background: Eosinophilic granulocytes are important for the human immune system. Many cationic proteins with cytotoxic activities, such as eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN), are released from activated eosinophils. ECP, with low RNase activity, is widely used as a biomarker for asthma. ECP inhibits cell viability and induces apoptosis to cells. However, the specific pathway underlying the mechanisms of ECP-induced cytotoxicity remains unclear. This study investigated ECP-induced apoptosis in bronchial epithelial BEAS-2B cells and elucidated the specific pathway during apoptosis.

Results: To address the mechanisms involved in ECP-induced apoptosis in human BEAS-2B cells, investigation was carried out using chromatin condensation, cleavage of poly (ADP-ribose) polymerase (PARP), sub-G1 distribution in cell cycle, annexin V labeling, and general or specific caspase inhibitors. Caspase-8-dependent apoptosis was demonstrated by cleavage of caspase-8 after recombinant ECP treatment, accompanied with elevated level of tumor necrosis factor alpha (TNF- α). Moreover, ECP-induced apoptosis was effectively inhibited in the presence of neutralizing anti-TNF- α antibody.

Conclusion: In conclusion, our results have demonstrated that ECP increased TNF- α production in BEAS-2B cells and triggered apoptosis by caspase-8 activation through mitochondria-independent pathway.

Background

Eosinophilic granulocytes, commonly called eosinophils, are leukocytes that develop in the bone marrow and differentiate from hematopoietic progenitor cells [1]. Eosinophils traffic into tissues, such as the gastrointestinal, genitourinary and respiratory tracts [2], and are recruited to airway tissues during the asthmatic inflammatory process [3]. Activated eosinophils release cytokines such as tumor necrosis factor alpha (TNF- α) [1] and granular toxic proteins. Among which eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) share 67% amino acid sequence identity [4] and play important roles in the pathogenesis of mammalian cells [5].

ECP is a member of the pancreatic-type extracellular ribonuclease (RNase) family, in which ECP and EDN are respectively named as RNase3 and RNase2 [6]. It has

been extensively investigated as an efficacious biomarker of airway inflammation such as asthma [7] and has been suggested as a causal factor in allergic respiratory disease [8]. ECP is a potent cytotoxic protein capable of killing cells of guinea pig tracheal epithelium [9], mammalian leukemia [10], epidermis carcinoma [9], and breast carcinoma [11] as well as non-mammalian cells such as parasites, bacteria, and viruses [12]. The molecular mechanisms of ECP cytotoxicity are not involved in its RNase activity [13]. Interestingly, we have previously shown that the signal peptide of ECP is toxic to cells lacking of the signal peptide peptidase, an intramembrane protease located in the endoplasmic reticulum (ER) [14] and it also triggers up-regulation of transforming growth factor alpha (TGF- α) expression in human cells [15]. Mature ECP devoid of the 27-residue signal peptide contains 133 residues with high positive charges [16]. Cellular uptake and cytotoxicity of RNases have been correlated with the pI value and positive charge [17,18]. We have recently reported that mature ECP is cytotoxic to human bronchial epithelial (BEAS-

* Correspondence: yklai@life.nthu.edu.tw

† Contributed equally

¹Institute of Biotechnology & Department of Life Science, National Tsing Hua University, Hsinchu, 30013 Taiwan

2B) cells by specific binding to cell surface heparan sulfate proteoglycans (HSPGs) followed by endocytosis [19,20].

Many RNases, such as EDN, Onconase (ONC), and ECP have been reported to induce apoptosis in cells [21-23]. In one such study, a synthetic peptide of EDN was found to induce apoptosis in Kaposi's sarcoma cells [22]. Moreover, ONC, one member of bullfrog RNase A superfamily, displays apoptosis to tumor cells [23]. A latest study indicated that ECP caused cytotoxicity in HL-60 and HeLa cells *via* caspase-3 like activity [21]. Accordingly, cytotoxic RNases play an important role in cell death. However, the mechanism of ECP-induced apoptosis is still not fully verified. Recent studies have shown that eosinophils can induce epithelial cell death *via* apoptosis and necrosis [24]. In addition, apoptosis of airway epithelium cells (AECs) has been reported as a mechanism for removing damaged cells to maintain AEC function such as immune and inflammatory modulators [25,26]. It has also been suggested that AECs in response to different external invasions (e.g., pathogens) can protect themselves [25]. However, the specific apoptosis pathway in ECP-induced human AEC death remains unclear.

Apoptosis, also called programmed cell death, is generally distinguished into two types—caspase-dependent and caspase-independent [27,28]—with the former being the major type. Caspases belong to the cysteinyl aspartate protease family and are classified as effectors (caspases-3, -7, and -6) and initiators (caspases-2, -8, -9, and -10) of programmed cell death. In addition, caspase-12 is reported to be an inflammatory caspase [29]. Currently caspase-dependent apoptosis is divided into three pathways: two intrinsic mitochondria- and ER-associated pathways [30,31] and one extrinsic death receptor-initiated pathway [32]. Mitochondrial membrane potential (MMP) represents a crucial check-point involving caspase-9, which leads to apoptosis [33]. A current study showed that ER stress response involved in caspase-12 could induce apoptosis [34], and consequently the ER stress-induced chaperones such as 78-kDa glucose-regulated protein (GRP78) were activated to rescue the cells. GRP78 inhibits apoptotic signaling through ER or non-ER stress [35]. Caspase-8-dependent apoptosis may be triggered by cell surface receptors belonging to the tumor gene superfamily, including CD95 (or Fas) [36,37], TNF receptor-1 (TNFR1) [38], and TNF-related apoptosis-inducing ligand (TRAIL) [39,40]. Another mechanism for initiating the proteolytic cascade is induced by engagement of TNFR, Fas/APO-1/CD95, triggering caspase-3 activation by activated-caspase-8 without involvement of mitochondria [41,42]. Regarding the ligand of TNFR, TNF- α , it has been reported to be released from epithelial cells [43] and activated

eosinophils [44]. Moreover, it is known that poly (ADP-ribose) polymerase (PARP) is cleaved by caspase-3, a downstream caspase of caspase-8, -9, and -12, and causes cell apoptosis [45].

In general, asthma patients have a higher concentration of ECP in serum, bronchoalveolar lavage, and sputum, along with tissue damage than healthy people [46-48]. Severe damage and shedding are commonly observed in asthmatic airway epithelium [49]. Therefore, understanding the mechanism of ECP-induced apoptosis might provide practical methods to treat asthma. Here we intended to determine if BEAS-2B cell death occurred primarily due to apoptosis after ECP treatments, and verified the pathway involved in apoptotic cells.


Results

rECP causes cell death and apoptosis

The effect of rECP on BEAS-2B cell viability was determined by the MTT assay. The rECP was added to the cell culture at concentrations of 0, 10, 20, 30, 40 and 50 μ M at 37°C for 48 h. rECP inhibited cell viability with an IC₅₀ of 21.03 μ M, and cell viability was rescued by general caspase inhibitor, Z-VAD-FMK (Figure 1A). After co-incubation with rECP, shrinkage and unattachment of the cells from culture plate were observed (Figure 1B). BEAS-2B is a human bronchial epithelial cell line which is quite similar to primary cell. To determine whether such cell death was related to apoptosis, the nuclei were stained with Hoechst 33342 to monitor condensation of nuclear chromatin. Bright spots in the rECP-treated cells indicated nuclei undergoing chromatin condensation, strongly suggesting that BEAS-2B cells underwent apoptosis (Figure 1C). Here, apoptosis was also evaluated by staining with annexin V, a reagent commonly used to detect early apoptosis. BEAS-2B cells were treated with 20 μ M rECP for 24 h. The treated BEAS-2B cells showed 14.5 \pm 0.1% apoptosis (Figure 1D). Besides, the characteristic DNA fragmentation upon treatment with rECP was observed (Additional file 1). In comparison with untreated cells, the data indicated that BEAS-2B cells underwent early apoptosis after treatment with rECP.

rECP alters cell cycle distribution in BEAS-2B cells


DNA damage is a general phenomenon in apoptotic cells and usually determined by sub-G1 cell cycle progression. To investigate whether caspase-9 and -12, markers of mitochondria and ER, respectively, were activated in BEAS-2B cells, specific pathway inducers were used as alternative apoptotic initiators for comparison. BEAS-2B cells were treated separately with 0.1 μ M staurosporin (STS), a strong mitochondrial damage inducer, and 1 μ M thapsigargin (TG), a strong ER response inducer, for 24 h and stained with PI prior to



sub-G1 DNA population analysis employing fluorescent-activated cell sorting (FACS) (Figure 2). The fraction of untreated control cells in sub-G1 was 2%, and that of cells treated with STS, rECP and TG was increased significantly up to 36%, 9% and 7%. Therefore, the increase of sub-G1 fraction in the individual treatments represented the cells undergoing apoptosis. Here TG and STS were able to induce apoptosis in BEAS-2B cells through the ER response and mitochondrial damage pathways, respectively.

rECP induces apoptosis in a caspase-dependent manner

In general, activation of the caspase cascade plays an important role in apoptosis. To identify possible involvement of caspases in ECP-induced apoptosis, BEAS-2B cells were treated with rECP in the presence or absence of general caspase inhibitor Z-VAD-FMK and specific caspase-9 and -12 inhibitors, Z-LE(OMe)HD(OMe)-FMK and Z-ATAD-FMK, respectively. The presence of cleaved poly (ADP-ribose) polymerase (PARP) was monitored to evaluate the degree of apoptosis. As compared with the control cells without drug treatment, apoptosis was clearly blocked by caspase inhibitors. The levels of cleaved PARP decreased 92% upon pre-treatment with Z-VAD-FMK (Figure 3A), suggesting that ECP-induced apoptosis proceeded *via* the caspase-dependent pathway. However, cells pre-treated with Z-LE(OMe)HD(OMe)-



FMK (Figure 3B) or Z-ATAD-FMK (Figure 3C) exhibited no effect upon treatment with rECP, suggesting that caspase-9 and caspase-12 were not the major pathways involved in cell death triggered by rECP.

rECP induces ER-independent apoptosis

The ER response is generally triggered by environmental stress and sometimes leads to apoptosis. Because GRP78 plays a crucial role in the ER response [50], the level of GRP78 expression in BEAS-2B cells treated with rECP was assessed by Western blotting and a *de novo* synthesis assay. Accumulated and newly synthesized GRP78 were detected using anti-GRP78 (Figure 4A) and metabolic labeling with [³⁵S]methionine (Figure 4B), respectively. The ratio of both accumulated and nascent GRP78 to actin did not change during rECP treatment. As for positive control, when the cells were treated with 1 μM TG, an ER toxin, a 2- to 4-fold increase in accumulated GRP78 after 4 to 24 h treatment was observed; moreover, newly synthesized GRP78 revealed a 4- to 6-fold increase after 4 to 24 h under the same condition. Taken together, these results implied that rECP-induced apoptosis was ER-independent, in consistence with the results of caspase-12 inhibitor treatment (Figure 3C).


rECP-induced apoptosis is not mitochondria-dependent

It has been reported that loss of MMP is involved in apoptosis [51]. To investigate whether mitochondrial

events were involved in rECP-induced apoptosis, MMP was measured by staining with MitoTracker (Red CMXRos) and analyzed by FACS. BEAS-2B cells treated with 1 μM STS, as a positive control, resulted in 37.9 ± 9% MMP, indicating that approximately 40% of mitochondria were damaged. However, cells treated with 20 and 40 μM rECP revealed MMP values of 5.1 ± 1.8% and 6.1 ± 2.7%, respectively, which did not substantially differ from the untreated control cells (3.3 ± 0.4%) (Figure 5). These results suggested that the caspase-9-dependent mitochondrial apoptotic pathway was not involved in rECP-induced apoptosis, in agreement with the results of caspase-9 inhibitor treatment (Figure 3B). Moreover, cells treated with 10 and 20 μM rECP did not alter cytochrome *c* release, strongly suggesting the notion that rECP did not cause damage in mitochondria (Additional file 2).

Caspase-8 is involved in rECP-induced apoptosis

Caspase-8 is a downstream target of the death receptor-initiated pathway [52]. To identify possible involvement of caspases-8 in ECP-induced apoptosis, BEAS-2B cells were treated with rECP in the presence or absence of caspase-8 inhibitor Z-IETD-FMK. The levels of cleaved PARP decreased 40% upon pre-treatment with Z-IETD-FMK (Figure 6A), suggesting that ECP-induced apoptosis proceeded possibly *via* the caspase-8-specific







Figure 4 Effect of rECP-induced apoptosis on ER response. BEAS-2B cells were treated with rECP or thapsigargin (TG; an ER toxin as a positive control) for the indicated times. The cells used to determine the ER response were incubated with 20 μ M rECP or 1 μ M TG for 0, 4, 8, 12, 16, 20 and 24 h. **(A)** Total cell lysates were resolved by 10% SDS-PAGE, and the relative accumulated GRP78 was investigated by western blotting with anti-GRP78 and anti-actin. **(B)** For *de novo* proteins synthesis, cells were labeled with [35 S]methionine for 2 h before harvesting. Equal amounts of labeled cell lysates were resolved by 10% SDS-PAGE followed by quantitative analysis. All data represent the arithmetic mean \pm SEM. * $P < 0.05$.



pathway. To examine caspase-8 and PARP activation during rECP-induced apoptosis, BEAS-2B cells were treated with 20 μ M rECP for 48 h. The presence of specific cleavage products of caspase-8 and PARP were activated (Figure 6B), suggesting that these precursors were activated and rECP-induced apoptosis was indeed mediated by caspase-8 pathway in BEAS-2B cells.

To confirm that induction of caspase-dependent apoptosis was not derived from lipopolysaccharide, a contaminant often observed in recombinant proteins produced in *E. coli*, rECP was treated with proteinase K (PNK) prior to addition to BEAS-2B cells. It was clear

that no PARP cleavage was generated in the presence of either heated rECP or the PNK-treated rECP mixture (Figure 6C), strongly suggesting that apoptosis was indeed induced by rECP itself but not by endotoxins or contaminants in the sample. Moreover, mutant rECP H15A/K38I/H128A (mECP), devoid of the RNase activity, also induced apoptosis, in consistent with the hypothesis that the RNase activity was not essential for cytotoxicity of ECP [13].

rECP-induced apoptosis is involved in TNF- α response

BEAS-2B cells treated with rECP induced TNF- α production and release (Figures 7). Secretion of TNF- α in the culture medium was monitored in BEAS-2B cells treated with rECP for periods from 0 to 48 h (Figure 7A), suggesting that TNF- α production in rECP-treated cells was time-dependent. An ELISA analysis showed that TNF- α accumulation in cell lysate of BEAS-2B cells significantly increased in those treated with rECP after 24 h (49.9 ± 0.5 pg/mg total proteins). The maximum of TNF- α production in the cells reached at 48 h (58.8 ± 0.6 pg/mg total protein). In addition, higher TNF- α level was detected in the supernatant of BEAS-2B cells treated with rECP for 48 h than control cells (16.9 ± 0.1 and 4.0 ± 0.6 pg/ml, respectively) (Figure 7B). In this study, we have found that mutant ECP lacking of RNase activity (mECP) can also induce TNF- α liberation; however, there is no significant increase of TNF- α liberation upon treating with RNase A (Additional file 3).

Previous results showed that eosinophils induced cells to undergo apoptosis accompanying with increasing TNF- α production [26]. To exclude the effect of TNF- α in rECP-induced apoptosis in BEAS-2B cells, an anti-TNF- α antibody (Ab) was used to deplete TNF- α in the culture medium. When BEAS-2B cells were pre-treated with anti-TNF- α Ab, the levels of cleaved PARP significantly decreased to 22% (Figure 7C). Taken together, we have provided the first direct evidence that rECP induced BEAS-2B cells to produce TNF- α , which in turn leads to apoptosis *via* caspase-8 dependent pathway.

Discussion

AECs play an important role in protecting themselves from external invasion by forming a physical barrier. It has been reported that concentrations of ECP of the sputum is positively correlated with airway inflammation and asthma severity [46], hence higher sputum ECP concentration up to μ M level was detected in asthmatic patients [7]. The patches of denuded epithelium were observed in airway biopsies of asthmatic patients [49]. ECP and EDN, having high sequence and structural similarity, are released from activated eosinophils. They inhibit the growth of HL-60 cells (human promyelocytic leukemia cells) [10] and Kaposi's sarcomas cells [53].




Figure 6 Effect of caspase-8 on rECP-induced apoptosis. (A) Cells were treated with 20 μ M caspase-8 inhibitor (Z-IETD) for 30 min before rECP treatment. After a 48-h incubation in the presence or absence of 20 μ M rECP, total cell lysates were resolved by 10% SDS-PAGE. Relative cleaved PARP was assessed by western blotting using anti-PARP and anti-actin followed by quantitative analysis. (B) BEAS-2B cells were cultured for 48 h in the presence or absence of 20 μ M rECP. Total cell lysates were resolved by 15% SDS-PAGE. Caspase-8 and PARP were analyzed by western blotting using anti-caspase-8 and anti-PARP. (C) rECP was incubated with proteinase K (PNK) (250 μ g/ml) for 12 h followed by heating in boiling water for 10 min. Cells were treated in the presence or absence of rECP (20 μ M), heated PNK (25 μ g/ml), heated mixtures (20 μ M rECP and 25 μ g/ml PNK), and rECP H15A/K38I/H128A mutant (20 μ M) for 48 h. All data represent the arithmetic mean \pm SEM. *** p < 0.001.




Figure 7 Effects of TNF- α on rECP-induced apoptosis. BEAS-2B cells were treated with 20 μ M rECP. (A) TNF- α was measured in cell lysates by rECP treatment for ranging from 0 to 48 h. (B) TNF- α was measured in cultured supernatant medium by rECP treatment for 48 h. All the TNF- α measurements were determined by ELISA assay. (C) To investigate the role of TNF- α in rECP-induced apoptosis, BEAS-2B cells were pretreated with 5 μ M anti-TNF- α Ab for 4 h before rECP treatment. The addition of IgG Ab to the medium of cells was used as controls in neutralization studies. All data represent the arithmetic mean \pm SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.

Although both ECP and EDN induce apoptosis in cells, the mechanism has not been fully elucidated [21,22]. Recently, ECP was shown to inhibit the viability of BEAS-2B cells as analyzed by MTT assay, but it has never been reported that ECP could cause apoptosis in BEAS-2B cells. Our results of increase in chromatin condensation, sub-G1 population, PARP cleavage, and DNA fragmentation strongly indicate that ECP induces apoptosis in BEAS-2B cells. The study by Trautmann et al. showed that rECP-induced cell death *via* necrosis in bronchial epithelial cells (ECs), which might be attributed to high sensitivity to rECP, and all rECP-induced apoptotic cells activated signals to necrosis in ECs [24]. In addition, the study by Nicotera et al. showed that apoptosis and necrosis death in cell were often intertwined; through apoptosis pathway, caspase activation could cause necrosis by promoting ion overload [54]. Cell type specific response may account for different sensitivity to ECP and different stage of cells in our case. Pre-treatment with general caspase inhibitor impedes ECP cytotoxicity, suggesting that ECP-induced apoptosis is caspase-dependent. It has been known that mitochondrial damage, ER response, and death receptor activation would trigger caspase-dependent apoptosis. Hence three specific caspase (caspase-8, -9 and -12) inhibitors were used to investigate the possible pathways during such caspase-dependent apoptosis. Most apoptosis is linked to mitochondria-related damage, but pre-treatment with a caspase-9 inhibitor did not show any effect in our case. MMP and cytochrome *c* release experiments also confirmed this point. In addition, pro-caspase-12 cleavage to form active caspase-12 may take place if the ER response has been activated [55]. Although the study shows that human caspase-12 is regarded as a pseudogene because of losing function with several mutations [56], Saleh et al. have reported that caspase-12 shows natural polymorphism in ethnic groups of African descent [57]. In this study, pre-treatment with a caspase-12 inhibitor, metabolite labeling and Western blotting for GRP78 indicated that rECP did not affect the ER response. Apparently rECP-induced apoptosis was not involved in ER response for the protein level of GRP78 was not altered with or without ECP treatment. Therefore, ECP-induced apoptosis was neither caspase-9 nor caspase-12 dependent. Alternatively, the death receptor pathway which undergoes caspase-8 signal transduction, might be involved in ECP-induced apoptosis. Caspase-8-dependent apoptosis may be triggered by cell surface death receptors such as TNFR and Fas...etc. [32]. Till now activation of the caspase-8 pathway in cells treated by eosinophils has never been reported. Recently, ECP was proved to induce apoptosis undergoing caspase-3 like pathway [21]. However, no correlation with caspase-8 has been mentioned.

In this study pre-treatment with caspase-8 inhibitor clearly demonstrated that apoptosis was mediated through caspase-8 activation, and cleavage of caspase-8 offered strong evidence to support this notion. This is the first study showing direct correlation between rECP and caspase-8 activation in bronchial epithelial cells, which in turn results in cell apoptosis.

TNF- α or FasL may serve as the death ligands to AECs during caspase-8-dependent apoptosis and TNF- α has been reported to induce apoptosis in AECs [26]. It has also been known that both ECP and TNF- α are released from activated eosinophils [26]. Epithelial cells release cytokines and growth factors such as IL-6, TNF- α and TGF- β under environmental stress to remove injured cells and recruit healthy cells [43]. However, there is no report indicating the correlation between rECP and TNF- α liberation. Trautmann et al. found that IFN- γ stimulated eosinophil lysate induced bronchial epithelial cells to undergo apoptosis [24]. TNF- α played an important role in IFN- γ stimulated eosinophil-induced apoptosis in bronchial epithelial cells, as evidenced by TNF- α antibody blocking experiment. Besides, previous study showed that co-culture with house dust mite-activated eosinophils and airway bronchial epithelial cells induced TNF- α release; the inhibition experiment further indicated that p38 MAPK and NF- κ B were involved in TNF- α release in eosinophil-AECs system [58]. Since ECP is the major component in eosinophils, it is possible that rECP induced TNF- α production may also involve NF- κ B and MAPK pathways. Here we hypothesized that up-regulated TNF- α , triggered by rECP treatment, was released to external environment, where it killed cells *via* a feedback mechanism. In this way, the death receptor-triggered pathway would be stimulated to promote apoptosis. As a result, ECP might be recognized by cells as portending pathogen invasion, thereby inducing certain immune responses such as cytokine production and apoptosis. In this study, it found that the inactive RNase, mECP, could still induce TNF- α production, but highly active RNase A showed no significant TNF- α production, strongly suggesting that RNase activity did not correlate with TNF- α production (Additional file 3).

TNF- α receptor activation triggered apoptosis can undergo either mitochondria-dependent pathway which is involved in tBid activation and triggers caspase-9 activation by releasing cytochrome *c*, or mitochondria-independent pathway [59]. In our study, caspase-9 inhibitor, MMP assays and cytochrome *c* release experiments all indicated that rECP did not induce mitochondrial response, hence the apoptosis underwent mitochondria-independent pathway. Previous study has reported that caspase-6 is able to activate caspase-8 and involved in mitochondrial response [60]. However, it was proved

that ECP-induced apoptosis did not require mitochondrial response; hence we speculated that caspase-8 was activated by TNFR pathway instead of caspase-6. Taken together, Figure 8 presents that ECP induces apoptosis involved in TNF- α -related caspase-8 activation through mitochondria-independent pathway.


Although ECP belongs to the pancreatic-type RNase family [6], its RNase activity is relatively weak. Moreover, the RNase activity of ECP is not essential for its cytotoxicity [13]. ECP, EDN, and RNase A (RNase 1) all belong to the pancreatic RNase family, and their RNase activities can be detected (Additional file 4). As illustrated in our additional file 5, ECP and mutant rECP H15A/K38I/H128A with low or no RNase activity have higher toxicity toward BEAS-2B cells, whereas EDN and RNase A with high RNase activity show no toxicity toward BEAS-2B cells. Accordingly, our study also confirms that rECP lacking of RNase activity retains cytotoxicity. On the contrary, human RNase A is highly enzymatically active in RNA degradation but has no cytotoxicity. Therefore, we suggest that the cytotoxicity of ECP is not correlated to the RNase activity.

Onconase (ONC), one member of bullfrog RNase A superfamily, displays apoptosis to tumor cells *via* caspase-9 dependent but caspase-8 independent pathway [23]. Different from ONC, in this study, ECP triggers apoptosis *via* caspase-8 dependent but caspase-9 independent pathway. Recently, ONC was found to enter cells by clathrin-dependent endocytosis [61]. However, ECP endocytosed into BEAS-2B cells by non-clathrin but lipid raft-dependent macropinocytosis [19]. Accordingly, we speculate that the mechanisms of toxic RNase endocytosis may activate different caspase pathways in target cells.

ECP endocytosis into BEAS-2B cells are facilitated by HSPGs [19]. Interestingly, HS was also detected on the surface of A549 cells (lung carcinoma cells) [62]. Consequently, we found that rECP could induce apoptosis in A549 cells too (data not shown). Taken together, HS plays an important role in toxin endocytosis and triggering apoptosis in lung epithelial cells. Through specific interaction between ECP and HS, ECP can target cancer cells that are rich in HS [63]. Our results suggest that ECP-induced apoptosis might provide novel therapies for specific cancer cells.

Conclusions

In summary, we found that rECP could inhibit BEAS-2B cell viability and induce apoptosis. Increase of TNF- α in cells and medium, as well as cleavage of caspase-8 in BEAS-2B cells were detected after rECP treatment. However, neither MMP nor ER response was observed in the rECP-induced apoptotic cells. In addition, caspase-9 and -12 inhibitor assays confirmed such



speculation. Thus, we clearly demonstrate that rECP causes BEAS-2B cell apoptosis mainly through TNF- α -mediated caspase-8 specific pathway in a mitochondria-independent manner. The knowledge of this molecular basis is pivotal in understanding the development of pathogenesis in asthma and shed a light on potential therapeutic applications.

Methods

Cell and cell culture

BEAS-2B cells purchased from American Type Culture Collection (ATCC) were maintained in RPMI-1640 medium (Sigma-Aldrich) supplemented with heat-inactivated 10% fetal calf serum (Gibco/Invitrogen), 100 U/ml penicillin, and 100 μ g/ml streptomycin sulfate. Cells were maintained in 9-cm culture dishes with 5% CO₂ at 37°C. Cells were sub-seeded in appropriate culture vessels (6- or 12-well plates) and incubated at 37°C for 24 h prior to all treatments.

Expression and purification of rECP and mutant ECP

Both recombinant ECP (rECP) and H15A/K38I/H128A mutant rECP (mECP) were expressed in *Escherichia coli* and purified as described [64] with minor modification. rECP and mECP containing a C-terminal His₆ tag were expressed in *E. coli* BL21(DE3) (Novagen) and purified by affinity column chromatography (BD Biosciences). For each preparation, 10 ml of overnight culture was inoculated into 1 L LB containing 100 μ g/ml ampicillin, and grown at 37°C for 6 h. Isopropyl- β -D-thiogalactopyranoside (IPTG, Sigma-Aldrich) was added to a final concentration of 0.5 mM, and after induction at 37°C for 6 h, the *E. coli* was harvested by centrifugation at 3000 rpm. rECP and mECP were collected from inclusion bodies that were refolded by dialysis in refolding buffer (20 mM Tris, 0.5 M arginine, 0.2 mM GSSG, 2 mM EDTA, 10% glycerol, pH 8.5). The purified rECP and mECP were concentrated by Amicon Ultra-15 (Millipore) and stored in phosphate-buffered saline (PBS) at -80°C until use. After purification, we used Endotoxin Removing Gel (Pierce) to remove LPS before rECP storage and also checked LPS residual level by HEK-Blue™ LPS Detection Kit (InvivoGen) before each treatment.

MTT cell viability assay

The toxicity effect of rECP on cell viability was determined by a colorimetric assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltertrazolium bromide (MTT) (Sigma-Aldrich) as described [65]. Briefly, cells (5,000~10,000) were seeded in 96-well plate and incubated overnight at 37°C, 5% CO₂. The cells were treated with the indicated concentration (up to 40 μ M) of rECP. After treatment with rECP for 48 h, 10 μ l MTT (5 mg/ml in PBS) was added to 90 μ l of culture medium/well

for 4 h. Levels of MTT were determined by measuring the absorbance at 570 nm.

Detection of chromatin condensation

Hoechst 33342 (1 μ g/ml) (Sigma-Aldrich) was added 20 min prior to the end of the incubation period in the dark. The cells were washed with cold PBS twice and fixed with 3.7% formaldehyde for 15 min. The nuclei of apoptotic cells were observed by fluorescence microscopy.

Detection of apoptosis by sub-G1 fractions and Annexin-V-FITC

To determine the sub-G1 fractions, detached BEAS-2B cells were fixed in 75% ethanol at -20°C overnight and centrifuged at 1000 \times g for 5 min to remove ethanol, followed by treatment with 50 μ g/ml RNase A and staining with 50 μ g/ml propidium iodide (PI) (Sigma-Aldrich) on ice for 30 min in the dark [66]. The stained cells were analyzed by fluorescence-activated cell sorting (FACS) (Becton Dickinson) according to the manufacturer's instructions. The levels of early apoptosis were determined using the Annexin-V-FITC Apoptosis Detection kit (BD Biosciences). The method was performed as described [67] with minor modification. After trypsinization, BEAS-2B cells were washed twice with cold PBS and resuspended in 1 \times binding buffer. The cell suspension (200 μ l) was transferred to 5-ml tubes, and 5 μ l annexin V was added. After incubation with annexin V for 5 min at 4°C, 5 μ l PI was added. The cells were incubated at 4°C in the dark for 15 min, and 800 μ l of binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl₂) was added before FACS analysis.

Detection of mitochondrial membrane potential (MMP)

To determine MMP, the detached BEAS-2B cells were stained with 100 nM MitoTracker Red CMXRos (Molecular Probes) in RPMI medium for 20 min at 37°C in the dark. After trypsinization, the stained cells were analyzed by FACS. Fluorescence of PI was collected in the FL2 or FL3 detector, and fluorescence of MitoTracker was collected in the FL3 detector. All data were evaluated using Cell Quest software (Becton Dickinson).

Caspase and TNF- α inhibitors treatment

Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD-FMK) (Calbiochem), benzyloxycarbonyl-Ile-Glu-Thr-Asp-fluoromethylketone (Z-IETD-FMK) (Calbiochem), benzyloxycarbonyl-Leu-Glu(OMe)-His-Asp(OMe)-fluoromethylketone (Z-LE(OMe)HD(OMe)-FMK) (Calbiochem), and benzyloxycarbonyl-Ala-Thr-Ala-Asp-fluoromethylketone (Z-ATAD-FMK) (BioVision) are irreversible cell-permeable inhibitors of the general caspase pathway, caspase-8-, caspase-9- and caspase-12-specific pathways, respectively [68]. For studies concerning the effect of inhibitors, each inhibitor (stored in 10 mM DMSO) was added to BEAS-2B cells at 20 μ M for 30 min prior to the addition of rECP.

For the TNF- α inhibitor studies, BEAS-2B cells were treated with rECP neutralized with/without anti-TNF- α antibody (Ab) (5 μ g/ml; Abcam). The addition of polyclonal rabbit IgG Ab (5 μ g/ml; Sigma-Aldrich) to the medium of cells was used as controls in inhibitor studies. The dose of the inhibitors was used in the information based on the efficacy in the inhibition of the activity of the cytokines but not cause cytotoxicity (trypan blue dye exclusion).

Western blotting

BEAS-2B cells treated with rECP neutralized with/without the inhibitors. Cell lysates were homogenized by sample buffer (100 mM Tris-HCl (pH 6.8), 2% Sodium Dodecyl Sulfate (SDS), 0.002% bromophenol blue, 20% glycerol, 10% β -mercaptoethanol (all from Sigma-Aldrich)). Those were subjected to SDS-PAGE and transferred onto nitrocellulose membranes (Amersham Biosciences). The following primary antibodies were used for immunodetection: rabbit anti-human poly(ADP-ribose) polymerase (PARP) (Cell Signaling), goat anti-human actin (Santa Cruz Biotechnology), mouse anti-human caspase-8 (Calbiochem), and rat anti-human GRP78 (Santa Cruz Biotechnology). Secondary antibodies conjugated to horseradish peroxidase (Santa Cruz Biotechnology) and the Western Blot Substrate kit (Pierce) were used to detect chemiluminescence.

De novo protein synthesis

Metabolic labeling of nascent proteins was conducted as described [69]. At the end of various treatment periods, the cells were washed with PBS twice, and replaced with RPMI medium containing [35 S]methionine (20 μ Ci/ml) for 2 h. After removal of the medium, the cells were washed with PBS twice and lysed with 2 \times sample buffer. Equal amounts of cells were heated at 100°C in sample buffer for 10 min and resolved by SDS-PAGE. The gel was dried for 2 h and exposed to X-ray film for 4 days before development.

Quantitative measurement of TNF- α

For determination of cell-associated cytokine concentrations, cell lysate was prepared using protein extract buffer containing 0.6 M KCl, 1% Triton X-100, 0.02 M Tris-HCl (pH7.0), 1.0 mM phenylmethylsulfonyl fluoride, and 50 μ g/ml aprotinin (all from Sigma-Aldrich). After centrifugation at 9,500 g for 3 min at 4°C, protein samples in the supernatant were immediately transferred to a clean tube, and the concentration assessed using DC protein assay kit (Bio-Rad). Supernatant and lysate TNF- α concentrations were determined using corresponding ELISA Ready-SET-Go kits (eBioscience) and expressed in pictograms of TNF- α per milligram of cellular protein. The optical density was detected using a VERSAmax microplate reader (Molecular Devices) and the levels of each cytokine were deduced from the

absorbance value by extrapolation from a standard curve generated in parallel.

DNA fragmentation

DNA fragmentation assay was conducted as described [70] with minor modification. Cells were washed twice in cold PBS and resuspended in 100 ml of lysis buffer (10 mM Tris-HCl, pH8, 1 mM EDTA, pH 8.0, 0.5%N-lauroyl sarcosine, 0.02 mg/ml RNase A, and 0.25 mg/ml proteinase K). After incubation for 10 min at 55°C, the sample was loaded into the 2% agarose gel. Electrophoresis was then performed in TBE buffer (89 mM Tris-base, 89 mM boric acid, 2 mM EDTA pH 8.0).

Cytochrome C release detection

Cytochrome C release detection assay was followed as described [70] with minor modification. Cells were put on ice for 10 min and washed twice in cold PBS. Cell pellets were then resuspended in 250 ml of buffer A (75 mM KCl, 1 mM Na₂HPO₄, 8 mM Na₂HPO₄, 250 mM sucrose, 230 mg/ml digitonin) and incubated on ice for 10 min. After centrifugation at 15,000 g for 10 min at 4°C, supernatant were kept to obtain the cytosolic fractions. The cytosolic fraction was mixed with an equal volume of 2 \times RIPA buffer (1 \times RIPA is 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS, 0.2 mM sodium orthovanadate, 50 mM sodium fluoride, 0.1 mg/ml phenyl methyl sulfonyl fluoride).

Ribonuclease assay

The RNase activity of the recombinant proteins against a yeast tRNA (Sigma-Aldrich) substrate was measured in 20 mM Tris-HCl buffer (pH 8.0) at 37°C. Purified RNase (30 pmol) was added into 50 μ l of the Tris buffer with 120 μ g of tRNA. The reaction was stopped by addition of 200 μ l 0.7% perchloric acid with 0.1% uranyl acetate and incubated on ice for 30 min. The insoluble tRNA was removed by centrifugation at 14,000 g for 15 min at 4°C. The amount of solubilized tRNA was determined by UV absorbance at 260 nm. The catalytic activity of the RNase was determined as the nanogram of RNA digested per second per nanomol of RNase used.

Statistical analysis

Results were described as mean \pm standard deviation. All statistical analysis was conducted by the statistical package SPSS13.0. The differences were investigated using Student's *t*-test and one-way analysis of variance (ANOVA). Values of *P* are considered to be statistically significant: **P* < 0.05, ***P* < 0.01; ****P* < 0.001.

List of abbreviations

Ad12SV40: adenovirus 12-SV40 virus hybrid; AECs: airway epithelium cells; ECP: eosinophil cationic protein; rECP: recombinant ECP; mECP: H15A/K38I/H128A mutant rECP; EDN: eosinophil derived neurotoxin; ER: endoplasmic reticulum; FACS: fluorescent-activated cell sorting; GRP78: 78-kDa glucose regulated protein; HS:

heparan sulfate; HSPG: heparan sulfate proteoglycan; MMP: mitochondrial membrane potential; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltertrazolium bromide; ONC: onconase; PARP: poly (ADP-ribose) polymerase; pI: isoelectric point; PI: propidium iodide; PNK: Proteinase K; RNase: ribonuclease; STS: staurosporin; TG: thapsigargin; TNF- α : tumor necrosis factor-alpha; TNFR1: TNF receptor-1; TRADD: TNFR-associated death domain; TRAIL: TNF-related apoptosis inducing ligand; Z-LE(OMe)HD(OMe)-FMK: benzyloxycarbonyl-Leu-Glu-(OMe)-His-Asp(OMe)-fluoromethylketone Z-IETD-FMK: Benzyloxycarbonyl-Ile-Glu-Thr-Asp-fluoromethylketone; Z-VAD-FMK: Benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone; Z-ATAD-FMK: benzyloxycarbonyl-Ala-Thr-Ala-Asp-fluoro-methylketone.

Additional file 1: Supplementary Figure 1. rECP induces DNA fragmentation in BEAS-2B cells. BEAS-2B cells (5×10^5) were incubated in a 10 cm dish in the absence or presence of 20 μ M of rECP for 48 h. DNA damage indicating apoptosis was determined by the DNA fragmentation.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2121-11-6-S1.TIFF>]

Additional file 2: Supplementary Figure 2. Effect of cytochrome c release on rECP treatment. BEAS-2B cells (5×10^4) were incubated in a 6 well plate in the absence or presence of 10, 20 μ M of rECP for 24 h. The cytosolic cytochrome c was detected by western blotting.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2121-11-6-S2.TIFF>]

Additional file 3: Supplementary Figure 3. Effects of TNF- α liberation on various RNases. BEAS-2B cells were treated with 20 μ M RNase A, rECP and mECP. TNF- α was measured in cell lysates by treatment for 48 h. All the TNF- α measurements were determined by ELISA assay. All data represent the arithmetic mean \pm SEM. * $P < 0.05$

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2121-11-6-S3.TIFF>]

Additional file 4: Supplementary Figure 4. RNase activities of recombinant eosinophil RNases degrading yeast tRNAs. The RNase activities of rECP and EDN were measured employing a standard assay with yeast tRNA as the substrate, and RNaseA as a positive control. The values indicate in nmol tRNA digested per pmol enzyme per second.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2121-11-6-S4.TIFF>]

Additional file 5: Supplementary Figure 5. Effect of different ribonucleases on cytotoxicity of BEAS-2B cells. Equal mounts of cells were cultured in 12-well plates in the presence of 20 μ M of rECP, mutant rECP, rEDN and RNase A for 48 h. The cleavage of PARP was detected by western blotting. * $P < 0.05$

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2121-11-6-S5.TIFF>]

Acknowledgements

This work was supported by the Veterans General Hospitals University System of the Taiwan Joint Research Program, (VGHUST 96-G2-02-5) to Y.-K. Lai, and National Science Council, Taiwan (NSC 97-2627-B-007-017; NSC 98-3112-B-007-005), CGMH-NTHU Joint Research (98N2421E1) and Veterans

General Hospitals University System of the Taiwan Joint Research Program, (VGHUST 98-P5-16) to M. D.-T. Chang.

Author details

¹Institute of Biotechnology Department of Life Science, National Tsing Hua University, Hsinchu, 30013 Taiwan. ²Institute of Molecular and Cellular Biology Department of Life Science, National Tsing Hua University, Hsinchu, 30013 Taiwan. ³Department of Allergy and Clinical Immunology, Taichung Veterans' General Hospital, Taichung, 40705 Taiwan. ⁴Department of Bioresources, Da-Yeh University, Changhua, 51591 Taiwan.

Authors' contributions

YKL and MDTC originated the project, supervised the overall conduct of the research. KCC and CWL carried out major experimental work in this study and drafted the manuscript. TCF and CWS performed data analysis. CHC assisted TNF- α detection. CTC helped rECP purification. SLF helped FACS experiment and data analysis. CCC participated in manuscript preparation. JJT advised manuscript drafting. All authors read and approved the final manuscript.

Received: 25 March 2009

Accepted: 20 January 2010 Published: 20 January 2010

References

1. Rothenberg ME, Hogan SP: **The eosinophil.** *Annual Review of Immunology* 2006, **24**:147-174.
2. Stenfeldt AL, Wenneras C: **Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils.** *Immunology* 2004, **112**(4):605-614.
3. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, Seveus L, Trulsson A: **Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease.** *Clinical and Experimental Allergy* 1999, **29**(9):1172-1186.
4. Durham SR, Loegering DA, Dunnette S, Gleich GJ, Kay AB: **Blood eosinophils and eosinophil-derived proteins in allergic-asthma.** *Journal of Allergy and Clinical Immunology* 1989, **84**(6):931-936.
5. Walsh GM: **Eosinophil granule proteins and their role in disease.** *Current Opinion in Hematology* 2001, **8**(1):28-33.
6. Boix E, Leonidas DD, Nikolovski Z, Nogues MV, Cuchillo CM, Acharya KR: **Crystal structure of eosinophil cationic protein at 2.4 angstrom resolution.** *Biochemistry* 1999, **38**(51):16794-16801.
7. Koh GCH, Shek LPC, Goh DYT, Van Bever H, Koh DSQ: **Eosinophil cationic protein: Is it useful in asthma? A systematic review.** *Respiratory Medicine* 2007, **101**(4):696-705.
8. Vila L, Sanz ML, Sanchez-Lopez G, Garcia-Aviles G, Dieguez I: **Variations of serum eosinophil cationic protein and tryptase, measured in serum and saliva, during the course of immediate allergic reactions to foods.** *Allergy* 2001, **56**(6):568-572.
9. Motojima S, Frigas E, Loegering DA, Gleich GJ: **Toxicity of eosinophil cationic proteins for guinea-pig tracheal epithelium invitro.** *American Review of Respiratory Disease* 1989, **139**(3):801-805.
10. Carreras E, Boix E, Navarro S, Rosenberg HF, Cuchillo CM, Nogues MV: **Surface-exposed amino acids of eosinophil cationic protein play a critical role in the inhibition of mammalian cell proliferation.** *Molecular and Cellular Biochemistry* 2005, **272**(1-2):1-7.
11. Ali S, Kaur J, Patel KD: **Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation.** *American Journal of Pathology* 2000, **157**(1):313-321.
12. Venge P: **Monitoring the allergic inflammation.** *Allergy* 2004, **59**(1):26-32.
13. Rosenberg HF: **Recombinant human eosinophil cationic protein - ribonuclease-activity is not essential for cytotoxicity.** *Journal of Biological Chemistry* 1995, **270**(14):7876-7881.
14. Wu CM, Chang MDT: **Signal peptide of eosinophil cationic protein is toxic to cells lacking signal peptide peptidase.** *Biochem Biophys Res Commun* 2004, **322**(2):585-592.
15. Chang HT, Kao YL, Wu CM, Fan TC, Lai YK, Huang KL, Chang YS, Tsai JJ, Chang MDT: **Signal peptide of eosinophil cationic protein upregulates**

- transforming growth factor- α expression in human cells. *Journal of Cellular Biochemistry* 2007, **100**(5):1266-1275.
16. Weiler JM, Edens RE, Gleich GJ: Eosinophil granule cationic proteins regulate complement. I. Activity on the alternative pathway. *J Immunol* 1992, **149**(2):643-648.
 17. Fuchs SM, Raines RT: Polyarginine as a multifunctional fusion tag. *Protein Sci* 2005, **14**(6):1538-1544.
 18. Futami J, Maeda T, Kitazoe M, Nukui E, Tada H, Seno M, Kosaka M, Yamada H: Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. *Biochemistry* 2001, **40**(25):7518-7524.
 19. Fan TC, Chang HT, Chen IW, Wang HY, Chang MD: A heparan sulfate-facilitated and raft-dependent macropinocytosis of eosinophil cationic protein. *Traffic* 2007, **8**(12):1778-1795.
 20. Fan TC, Fang SL, Hwang CS, Hsu CY, Lu XA, Hung SC, Lin SC, Chang MD: Characterization of molecular interactions between eosinophil cationic protein and heparin. *J Biol Chem* 2008, **283**(37):25468-25474.
 21. Navarro S, Aleu J, Jimenez M, Boix E, Cuchillo CM, Nogues MV: The cytotoxicity of eosinophil cationic protein/ribonuclease 3 on eukaryotic cell lines takes place through its aggregation on the cell membrane. *Cell Mol Life Sci* 2008, **65**(2):324-337.
 22. Dricu A, Sergiu-Bogdan C, Brismar K, Biberfeld P, Andersson LC: A synthetic peptide derived from the human eosinophil-derived neurotoxin induces apoptosis in Kaposi's sarcoma cells. *Anticancer Research* 2004, **24**(3A):1427-1432.
 23. Iordanov MS, Ryabinina OP, Wong J, Dinh TH, Newton DL, Rybak SM, Magun BE: Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: Evidence for cytotoxic mechanisms different from inhibition of protein synthesis. *Cancer Research* 2000, **60**(7):1983-1994.
 24. Trautmann A, Schmid-Grendelmeier P, Kruger K, Cramer R, Akdis M, Akkaya A, Brocker EB, Blaser K, Akdis CA: T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. *Journal of Allergy and Clinical Immunology* 2002, **109**(2):329-337.
 25. Jyonouchi H: Airway epithelium and apoptosis. *Apoptosis* 1999, **4**(6):407-417.
 26. Tesfaigzi Y: Roles of apoptosis in airway epithelia. *American Journal of Respiratory Cell and Molecular Biology* 2006, **34**(5):537-547.
 27. Fesik SW, Shi YG: Structural biology - Controlling the caspases. *Science* 2001, **294**(5546):1477-1478.
 28. Kroemer G, Martin SJ: Caspase-independent cell death. *Nature Medicine* 2005, **11**(7):725-730.
 29. Earnshaw WC: Apoptosis - A cellular poison cupboard. *Nature* 1999, **397**(6718):387.
 30. Ferri KF, Kroemer G: Organelle-specific initiation of cell death pathways. *Nature Cell Biology* 2001, **3**(11):E255-E263.
 31. Riedl SJ, Shi YG: Molecular mechanisms of caspase regulation during apoptosis. *Nature Reviews Molecular Cell Biology* 2004, **5**(11):897-907.
 32. Philchenkov A: Caspases: potential targets for regulating cell death. *Journal of Cellular and Molecular Medicine* 2004, **8**(4):432-444.
 33. Kroemer G, Galluzzi L, Brenner C: Mitochondrial membrane permeabilization in cell death. *Physiological Reviews* 2007, **87**(1):99-163.
 34. Nakanishi K, Dohmae N, Morishima N: Endoplasmic reticulum stress increases myofiber formation in vitro. *Faseb Journal* 2007, **21**(11):2994-3003.
 35. Yu ZF, Luo H, Fu WM, Mattson MP: The endoplasmic reticulum stress-responsive protein GRP78 protects neurons against excitotoxicity and apoptosis: Suppression of oxidative stress and stabilization of calcium homeostasis. *Experimental Neurology* 1999, **155**(2):302-314.
 36. Kim PKM, Park SY, Koty PP, Hua Y, Luketich JD, Billiar TR: Fas-associating death domain protein overexpression induces apoptosis in lung cancer cells. *Journal of Thoracic and Cardiovascular Surgery* 2003, **125**(6):1336-1342.
 37. Kriehoff E, Milovic-Holm K, Hofmann TG: FLASH meets nuclear bodies - CD95 receptor signals via a nuclear pathway. *Cell Cycle* 2007, **6**(7):771-775.
 38. Lisa RJ, Borysenko CW, Blair H: Tumor Necrosis Factor Family Receptors Regulating Bone Turnover: New Observations in Osteoblastic and Osteoclastic Cell Lines. *Ann N Y Acad Sci* 2007, **1116**:432-443.
 39. Aktas O, Schulze-Topphoff U, Zipp F: The role of TRAIL/TRAIL receptors in central nervous system pathology. *Frontiers in Bioscience* 2007, **12**:2912-2921.
 40. Shankar S, Siddiqui I, Srivastava RK: Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. *Molecular and Cellular Biochemistry* 2007, **304**(1-2):273-285.
 41. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, et al: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. *Cell* 1996, **85**(6):817-827.
 42. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. *Cell* 1996, **85**(6):803-815.
 43. Polito AJ, Proud D: Epithelial cells as regulators of airway inflammation. *Journal of Allergy and Clinical Immunology* 1998, **102**(5):714-718.
 44. Faccioli LH, Vargaftig BB, Medeiros AI, Malheiros A: Cytokines in the modulation of eosinophilia. *Mem Inst Oswaldo Cruz* 1997, **92**(Suppl 2):109-114.
 45. Duriez PJ, Shah GM: Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. *Biochem Cell Biol* 1997, **75**(4):337-349.
 46. Kim CK, Kim JT, Kang H, Yoo Y, Koh YY: Sputum eosinophilia in cough-variant asthma as a predictor of the subsequent development of classic asthma. *Clinical and Experimental Allergy* 2003, **33**(10):1409-1414.
 47. Kim CK, Kim SW, Kim YK, Kang H, Yu JH, Yoo Y, Koh YY: Bronchoalveolar lavage eosinophil cationic protein and interleukin-8 levels in acute asthma and acute bronchiolitis. *Clinical and Experimental Allergy* 2005, **35**(5):591-597.
 48. Munthe-Kaas MC, Gerritsen J, Carlsen KH, Undlien D, Egeland T, Skinningsrud B, Torres T, Carlsen KL: Eosinophil cationic protein (ECP) polymorphisms and association with asthma, s-ECP levels and related phenotypes. *Allergy* 2007, **62**(4):429-436.
 49. Cohn L, Elias JA, Chupp GL: Asthma: mechanisms of disease persistence and progression. *Annu Rev Immunol* 2004, **22**:789-815.
 50. Lee AS: The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. *Methods* 2005, **35**(4):373-381.
 51. Debatin KM, Poncet D, Kroemer G: Chemotherapy: targeting the mitochondrial cell death pathway. *Oncogene* 2002, **21**(57):8786-8803.
 52. Cho SG, Choi EJ: Apoptotic signaling pathways: caspases and stress-activated protein kinases. *J Biochem Mol Biol* 2002, **35**(1):24-27.
 53. Newton DL, Rybak SM: Unique recombinant human ribonuclease and inhibition of Kaposi's sarcoma cell growth. *Journal of the National Cancer Institute* 1998, **90**(23):1787-1791.
 54. Nicotera P, Melino G: Regulation of the apoptosis-necrosis switch. *Oncogene* 2004, **23**(16):2757-2765.
 55. Masud A, Mohapatra A, Lakhani SA, Ferrandino A, Hakem R, Flavell RA: Endoplasmic reticulum stress-induced death of mouse embryonic fibroblasts requires the intrinsic pathway of apoptosis. *Journal of Biological Chemistry* 2007, **282**(19):14132-14139.
 56. Fischer H, Koenig U, Eckhart L, Tschachler E: Human caspase 12 has acquired deleterious mutations. *Biochem Biophys Res Commun* 2002, **293**(2):722-726.
 57. Saleh M, Vaillancourt JP, Graham RK, Huyck M, Srinivasula SM, Alnemri ES, Steinberg MH, Nolan V, Baldwin CT, Hotchkiss RS, et al: Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. *Nature* 2004, **429**(6987):75-79.
 58. Wong CK, Li ML, Wang CB, Ip WK, Tian YP, Lam CW: House dust mite allergen Der p 1 elevates the release of inflammatory cytokines and expression of adhesion molecules in co-culture of human eosinophils and bronchial epithelial cells. *Int Immunol* 2006, **18**(8):1327-1335.
 59. Heinrich M, Neumeyer J, Jakob M, Hallas C, Tchikov V, Winoto-Morbach S, Wickel M, Schneider-Brachert W, Trauzold A, Hethke A, et al: Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. *Cell Death Differ* 2004, **11**(5):550-563.
 60. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, et al: Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. *J Cell Biol* 1999, **144**(2):281-292.
 61. Rodriguez M, Torrent G, Bosch M, Rayne F, Dubremetz JF, Ribo M, Benito A, Vilanova M, Beaumelle B: Intracellular pathway of Onconase that enables its delivery to the cytosol. *J Cell Sci* 2007, **120**(Pt 8):1405-1411.

62. Berry L, Andrew M, Post M, Ofosu F, O'Brodovich H: **A549 lung epithelial cells synthesize anticoagulant molecules on the cell surface and matrix and in conditioned media.** *Am J Respir Cell Mol Biol* 1991, **4**(4):338-346.
63. Fjeldstad K, Kolset SO: **Decreasing the metastatic potential in cancers - Targeting the heparan sulfate proteoglycans.** *Current Drug Targets* 2005, **6**(6):665-680.
64. Boix E, Nikolovski Z, Moiseyev GP, Rosenberg HF, Cuchillo CM, Nogues MV: **Kinetic and product distribution analysis of human eosinophil cationic protein indicates a subsite arrangement that favors exonuclease-type activity.** *Journal of Biological Chemistry* 1999, **274**(22):15605-15614.
65. Hansen MB, Nielsen SE, Berg K: **Re-examination and further development of a precise and rapid dye method for measuring cell-growth cell kill.** *Journal of Immunological Methods* 1989, **119**(2):203-210.
66. Ibuki Y, Goto R: **Suppression of apoptosis by UVB irradiation: Survival signaling via P13-kinase/Akt pathway.** *Biochem Biophys Res Commun* 2000, **279**(3):872-878.
67. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS: **Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation.** *J Biol Chem* 2003, **278**(23):20915-20924.
68. Partheniou F, Kelsey SM, Srinivasula SM, Newland AC, Alnemri ES, Jia L: **c-IAP1 blocks TNF alpha-mediated cytotoxicity upstream of caspase-dependent and -independent mitochondrial events in human leukemic cells.** *Biochem Biophys Res Commun* 2001, **287**(1):181-189.
69. Chang YS, Lee LC, Sun FC, Chao CC, Fu HW, Lai YK: **Involvement of calcium in the differential induction of heat shock protein 70 by heat shock protein 90 inhibitors, geldanamycin and radicicol, in human non-small cell lung cancer H460 cells.** *J Cell Biochem* 2006, **97**(1):156-165.
70. Paquette JC, Guerin PJ, Gauthier ER: **Rapid induction of the intrinsic apoptotic pathway by L-glutamine starvation.** *J Cell Physiol* 2005, **202**(3):912-921.

doi:10.1186/1471-2121-11-6

Cite this article as: Chang et al.: TNF- α Mediates Eosinophil Cationic Protein-induced Apoptosis in BEAS-2B Cells. *BMC Cell Biology* 2010 **11**:6.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

